CHMP offers approval recomendation for potential diabetes treatment

The Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency this week recommended the approval of saxa/dapa for use in treating type-2 diabetes.

This medicine combines saxagliptin and dapagliflozin in order to allow improved glycemic control for cases where metformin, sulphonylurea and the two separate components of saxa/dapa are not effective. This proposed treatment would be utilized for adults that are at least 18 years old and have type-2 diabetes.

This medication was developed by AstraZeneca, a pharmaceutical company that is focused on the development of disease treatments. Recent efforts have been placed in the development of treatment options for diabetes.

Following the recommendation from CHMP, this medication is set to be reviewed by the European Commission. Should the commission approve it, it would be valid in 28 member states within the European Union and Norway, Iceland and Liechtenstein.

The submission to the CHMP and the European Commission was based on three studies. Two of these indicated that there was a significant reduction of HbA1c, which refers to glycated hemoglobin. Diabetes.co.uk reports that this measurement is how clinicians are able to determine blood sugar levels over a select period of time.